Brokers Issue Forecasts for ImmunityBio FY2026 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for ImmunityBio in a research note issued on Thursday, October 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.26) per share for the year, up from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.44) per share.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The business had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million.

Other analysts also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group upped their price target on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Finally, Piper Sandler restated an “overweight” rating and set a $16.00 price target on shares of ImmunityBio in a research note on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $8.77 on Wednesday. The firm’s 50 day moving average price is $8.61 and its 200-day moving average price is $7.99. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. The firm has a market cap of $9.29 billion, a P/E ratio of -9.04 and a beta of 0.02.

Institutional Trading of ImmunityBio

A number of large investors have recently modified their holdings of the stock. Fortress Financial Solutions LLC purchased a new position in ImmunityBio in the third quarter worth approximately $105,000. Firethorn Wealth Partners LLC grew its holdings in ImmunityBio by 107.9% during the 3rd quarter. Firethorn Wealth Partners LLC now owns 25,475 shares of the company’s stock worth $240,000 after acquiring an additional 13,219 shares in the last quarter. Courier Capital LLC increased its position in shares of ImmunityBio by 100.0% in the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company’s stock valued at $1,057,000 after purchasing an additional 56,000 shares during the last quarter. GAMMA Investing LLC increased its position in shares of ImmunityBio by 262.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company’s stock valued at $36,000 after purchasing an additional 2,756 shares during the last quarter. Finally, Collective Family Office LLC raised its holdings in shares of ImmunityBio by 2.6% in the 3rd quarter. Collective Family Office LLC now owns 161,254 shares of the company’s stock valued at $1,522,000 after purchasing an additional 4,054 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Insider Activity

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares of the company’s stock, valued at $1,053,244.50. This trade represents a 44.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director owned 2,777,788 shares of the company’s stock, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune response against cancer and infectious diseases. The company’s approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.